BMS links with Apexigen to test cancer immunotherapy combo

Source: Pharma Times, April 2017

Bristol-Myers Squibb and Apexigen are to test a combination of Opdivo and the latter’s investigational compound APX005M in patients with advanced solid tumours.

The proposed collaboration will look at the safety, tolerability and preliminary efficacy of the combination in second-line metastatic non-small lung cancer patients who have failed prior chemotherapy, and in metastatic melanoma patients who have failed prior immuno-oncology therapy.

Preclinical data incidate that APX005M mimics the endogenous immune activation process through activation of CD40, a receptor on the surface of antigen presenting cells of the immune system which plays a fundamental role in the activation of both innate and adaptive immune system mechanisms.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories